5NRA.F NANOBIOTIX S.A. SP.ADR
- Market cap
- EUR 1.41B
- P/E
- -
- P/B
- 59.16x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 5NRA.F undervalued?
Graham numberThe Graham number of NANOBIOTIX S.A. SP.ADR cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANOBIOTIX S.A. SP.ADR fundamental analysis
No fundamental analysis for NANOBIOTIX S.A. SP.ADR yet.
NANOBIOTIX S.A. SP.ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANOBIOTIX S.A. SP.ADR
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to de…
Full company profileNANOBIOTIX S.A. SP.ADR financial statements
NANOBIOTIX S.A. SP.ADR annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 10.0K | 0.00 | 30.1M | -11.6M | 29.6M |
| Operating Income | -52.6M | -46.7M | -26.8M | -68.4M | -10.8M |
| EBITDA | - | -49.7M | -30.1M | -58.3M | -12.1M |
| Net Income | -47.0M | -57.0M | -39.7M | -68.1M | -24.0M |
| EPS | -1.35 | -1.64 | -0.84 | -1.44 | -0.50 |
| Balance Sheet | |||||
| Total Assets | 102M | 59.8M | 93.9M | 67.4M | 67.8M |
| Total Liabilities | 75.0M | 86.8M | 95.7M | 133M | 152M |
| Shareholders' Equity | 26.8M | -27.0M | -1.84M | -65.7M | -84.5M |
| Cash & Short-term Investments | 83.9M | 41.4M | 75.3M | 49.7M | 52.8M |
| Cash Flow | |||||
| Operating Cash Flow | -29.9M | -37.1M | -12.5M | -19.6M | -33.4M |
| Capital Expenditure | 233K | 93.0K | 337K | 848K | 546K |
| Free Cash Flow | -30.1M | -37.2M | -12.8M | -20.4M | -34.0M |
| Ratios | |||||
| ROE | -175.4% | - | - | - | - |
| ROA | -46.2% | -95.4% | -42.3% | -101.1% | -35.4% |
| Net Profit Margin | -470,030.0% | - | -132.1% | - | -80.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NANOBIOTIX S.A. SP.ADR dividends
NANOBIOTIX S.A. SP.ADR has not paid dividends in the last 5 fiscal years.
Who owns NANOBIOTIX S.A. SP.ADR
- Insiders 0.00%
- Institutions 11.96%
- Public & others 88.04%
- Shares outstanding 50.9M
- Free float 35.1M
NANOBIOTIX S.A. SP.ADR company profile
- Company name
- NANOBIOTIX S.A. SP.ADR
- Ticker
- 5NRA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 98
- Fiscal year end
- December
- Address
- 60 rue de Wattignies, Paris, France, 75012
- Phone
- 33 1 40 26 04 70
- Website
- nanobiotix.com
About NANOBIOTIX S.A. SP.ADR
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANOBIOTIX S.A. SP.ADR management
9- Dr. Laurent Levy Ph.D.Co-Founder, President of the Executive Board & CEO · born 1973
- Ms. Anne-Juliette Hermant M.A.Chief People Officer & Member of Executive Board · born 1974
- Dr. Louis Kayitalire M.D.Chief Medical Officer & Member of Executive Board · born 1959
- Mr. Earl J. Bergey Ph.d.Co-Founder · born 1955
- Mr. Arnd Christ MBACFO & Member of Executive Board · born 1966
- Mr. Brandon OwensVP of Strategic Marketing & Corporate Communication
- Ms. Margaret GalluzziVP & Global Head of Clinical Operations
- Dr. Leonard A. Farber M.D.Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board
- Ms. Anne-Sophie LariviereChief Product Innovation & Delivery Officer